p53 mutations and overexpression affect prognosis of ovarian endometrioid cancer but not clear cell cancer

Okuda T, Tsuyoshi Okuda, Junko Otsuka, Otsuka J, Akihiko Sekizawa, Sekizawa A, Saito H, Hiroshi Saito, Makino R, Reiko Makino, Miki Kushima, Kushima M, Antonio Farina, Yuzuru Kuwano, Kuwano Y, Takashi Okai, Okai T
Gynecologic Oncology · 2003 · vol. 88(3) , pp. 318–325 · doi:10.1016/s0090-8258(02)00149-x · PMID:12648581 · W1986799387
article OA: closed CC0 ⤵ 23 in-corpus citations
View on OpenAlex View on PubMed View at publisher
⚙ AI-generated summary by claude@2026-06, 2026-06-07 ⓘ

This study investigated the impact of p53 mutations and overexpression on patient outcomes in ovarian endometrioid and clear cell cancers, finding a significant prognostic effect only in endometrioid cancer.

One-sentence paraphrase of the abstract; not a substitute for reading it. No clinical advice. How this works

Abstract

ObjectiveAlthough ovarian clear cell adenocarcinoma (OCCA) and ovarian endometrioid adenocarcinoma (EC) are considered to be closely related to endometriosis, the mechanisms of carcinogenesis of these two malignancies and malignant transformation of endometriosis are unclear. In this study, we examined the biology of OCCA and EC by performing large-scale analysis of K-ras activation and p53 mutation and overexpression in these malignancies. The results were subsequently analyzed for correlation with the clinicopathologic data.MethodsIn the present study of OCCA and EC, we obtained clinicopathological data and analyzed frequency of mutations and overexpression of K-ras and p53. DNA was extracted from formalin-fixed, paraffin-embedded tissue, and target sequences were amplified in vitro by polymerase chain reaction. The DNA was analyzed for K-ras and p53 mutations by testing for single-strand conformation polymorphisms and by direct sequencing. Immunohistochemical staining was performed using p53 monoclonal antibody. Univariate analysis was performed using the Kaplan-Meier algorithm, and differences in survival were analyzed using the log rank test. The prognostic significance of the studied variables for survival was assessed using multivariate analysis with Cox regression analysis.ResultsK-ras mutation was detected in 16.2% (6/37) of OCCA patients and 3.7% (1/27) of EC patients. No evidence of p53 mutation was detected in OCCA patients, but p53 mutation was detected in 63.0% of EC patients; these findings are consistent with the results of p53 immunohistochemistry. No statistical significance was observed for K-ras mutation in OCCA or EC. In EC patients, the absence of endometriosis and p53 overexpression was associated with a poorer survival. In OCCA patients tubulocystic and papillary histotype as well as stage II correlated with a worse survival.Conclusionsp53 mutation, which was found in 63% of EC tumors, is an independent prognostic factor for EC patients. However, no p53 mutation was found in OCCA tumors. K-ras mutations did not affect survival of OCCA or EC patients.

My notes (saved in your browser only)

MeSH descriptors

Adenocarcinoma, Clear Cell Carcinoma, Endometrioid Genes, p53 Mutation Ovarian Neoplasms Adenocarcinoma, Clear Cell Adenocarcinoma, Clear Cell Adenocarcinoma, Clear Cell Adult Aged Carcinoma, Endometrioid Carcinoma, Endometrioid Carcinoma, Endometrioid Codon Female Genes, p53 Genes, ras Genes, ras Humans Immunohistochemistry

Citation neighborhood

Papers in the corpus that this work cites (lower rings, blue) and that cite this one (upper rings, green). Dot size scales with the paper's in-corpus citation count — bigger dot = more influential within the endo/adeno field. Click a dot to open that paper. [ expand to 2 hops ] — adds papers reached through this work's immediate citers/citees. Heavier; up to 60 extra dots.

References (47)

Cited by (23)

Source provenance

europepmc
last seen: 2026-08-04T06:16:37.499272+00:00
openalex
last seen: 2026-06-10T17:14:06.276822+00:00
pubmed
last seen: 2026-05-13T22:12:55.732728+00:00
License: CC0 · commercial use OK